JP2000514453A5 - - Google Patents

Download PDF

Info

Publication number
JP2000514453A5
JP2000514453A5 JP1998505806A JP50580698A JP2000514453A5 JP 2000514453 A5 JP2000514453 A5 JP 2000514453A5 JP 1998505806 A JP1998505806 A JP 1998505806A JP 50580698 A JP50580698 A JP 50580698A JP 2000514453 A5 JP2000514453 A5 JP 2000514453A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998505806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000514453A (ja
JP4368421B2 (ja
Filing date
Publication date
Priority claimed from IL11883696A external-priority patent/IL118836A/xx
Application filed filed Critical
Publication of JP2000514453A publication Critical patent/JP2000514453A/ja
Publication of JP2000514453A5 publication Critical patent/JP2000514453A5/ja
Application granted granted Critical
Publication of JP4368421B2 publication Critical patent/JP4368421B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50580698A 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物 Expired - Lifetime JP4368421B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL118836 1996-07-11
PCT/IL1997/000205 WO1998002152A1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan

Publications (3)

Publication Number Publication Date
JP2000514453A JP2000514453A (ja) 2000-10-31
JP2000514453A5 true JP2000514453A5 (en:Method) 2005-03-10
JP4368421B2 JP4368421B2 (ja) 2009-11-18

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50580698A Expired - Lifetime JP4368421B2 (ja) 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物

Country Status (12)

Country Link
US (1) US6277886B1 (en:Method)
EP (1) EP0929298B1 (en:Method)
JP (1) JP4368421B2 (en:Method)
CN (1) CN1149985C (en:Method)
AT (1) ATE328590T1 (en:Method)
AU (1) AU3188097A (en:Method)
CA (1) CA2260037C (en:Method)
DE (1) DE69736066T2 (en:Method)
HU (1) HU226961B1 (en:Method)
IL (1) IL118836A (en:Method)
NO (1) NO326052B1 (en:Method)
WO (1) WO1998002152A1 (en:Method)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
ES2588780T3 (es) 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
JP2007512319A (ja) * 2003-11-25 2007-05-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 心臓血管障害及び疾患を治療するための組成物及び方法
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
AU2005330504B2 (en) 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JP5738509B2 (ja) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CN101325871B (zh) * 2005-12-09 2013-04-10 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil用于神经保护的用途
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
BRPI0718339A2 (pt) * 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
DK2101569T3 (da) * 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
CA2727017A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing and drying solid rasagiline base
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
EP3517103A1 (en) 2010-02-03 2019-07-31 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
EA201490760A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. R(+)-n-метилпропаргиламиноиндан
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
MX2015002062A (es) 2012-08-17 2015-06-05 Teva Pharma Formulaciones parenterales de rasagilina.
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
WO1995018617A1 (en) * 1994-01-10 1995-07-13 Teva Pharmaceutical Industries Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Similar Documents

Publication Publication Date Title
JP2000502280A5 (en:Method)
JP2000501771A5 (en:Method)
JP2000501599A5 (en:Method)
JP2000501018A5 (en:Method)
JP2000500076A5 (en:Method)
JP2000501324A5 (en:Method)
JP2000502472A5 (en:Method)
JP2000501825A5 (en:Method)
JP2000501338A5 (en:Method)
JP2001503324A5 (en:Method)
JP2000500874A5 (en:Method)
JP2000502425A5 (en:Method)
JP2000502485A5 (en:Method)
JP2000502568A5 (en:Method)
JP2000501774A5 (en:Method)
JP2000500912A5 (en:Method)
JP2000502570A5 (en:Method)
JP2000501876A5 (en:Method)
JP2000501744A5 (en:Method)
JP2000501229A5 (en:Method)
JP2000502316A5 (en:Method)
JP2000500857A5 (en:Method)
JP2000502714A5 (en:Method)
JP2000501569A5 (en:Method)
JP2000500184A5 (en:Method)